Artiva Biotherapeutics, Inc. (ARTV) stock
ARTVNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$3.96−0.05 (-1.25%)
Close on Nov 16, 2026Market cap $193.61MP/E –Yield –
Artiva Biotherapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Artiva Biotherapeutics's operating margin for the twelve months ending Dec 31, 2024 was -26805.6%. For fiscal 2024 it was -26805.6%, against -91.6% the year before.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | -26805.6% | −26714.0 |
| FY2023 | Dec 31, 2023 | -91.6% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2024 | Mar 31, 2024 | -5773.7% | – |
| Q4 FY2023 | Dec 31, 2023 | -509.4% | – |
| Q3 FY2023 | Sep 30, 2023 | 40.6% | – |
| Q2 FY2023 | Jun 30, 2023 | -338.1% | – |
See a number that looks wrong?